- Home
- IMAB vs ENGN Comparison
IMAB vs ENGN Comparison
Compare IMAB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ENGN
- Stock Information
- Founded
- IMAB 2014
- ENGN 1999
- Country
- IMAB United States
- ENGN Canada
- Employees
- IMAB N/A
- ENGN N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- IMAB Health Care
- ENGN
- Exchange
- IMAB Nasdaq
- ENGN Nasdaq
- Market Cap
- IMAB 200.9M
- ENGN 191.1M
- IPO Year
- IMAB 2020
- ENGN N/A
- Fundamental
- Price
- IMAB $4.87
- ENGN $3.68
- Analyst Decision
- IMAB Strong Buy
- ENGN Buy
- Analyst Count
- IMAB 3
- ENGN 7
- Target Price
- IMAB $6.33
- ENGN $23.29
- AVG Volume (30 Days)
- IMAB 4.2M
- ENGN 102.4K
- Earning Date
- IMAB 05-15-2025
- ENGN 09-09-2025
- Dividend Yield
- IMAB N/A
- ENGN N/A
- EPS Growth
- IMAB N/A
- ENGN N/A
- EPS
- IMAB N/A
- ENGN N/A
- Revenue
- IMAB N/A
- ENGN N/A
- Revenue This Year
- IMAB N/A
- ENGN N/A
- Revenue Next Year
- IMAB N/A
- ENGN N/A
- P/E Ratio
- IMAB N/A
- ENGN N/A
- Revenue Growth
- IMAB N/A
- ENGN N/A
- 52 Week Low
- IMAB $0.60
- ENGN $2.65
- 52 Week High
- IMAB $5.90
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- IMAB 75.47
- ENGN 50.21
- Support Level
- IMAB $3.30
- ENGN $3.52
- Resistance Level
- IMAB $3.94
- ENGN $3.89
- Average True Range (ATR)
- IMAB 0.58
- ENGN 0.27
- MACD
- IMAB 0.23
- ENGN -0.02
- Stochastic Oscillator
- IMAB 76.12
- ENGN 32.86
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.